Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Johnson & Johnson Innovative Medicine’s Carvykti, have given hope to patients with relapsed/refractory (R/R) non-Hodgkin’s…
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | 2023
CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients…
Chimeric Antigen Receptor (CART) T-Cell Therapy | Access & Reimbursement | US | 2022
CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | TBD | US | 2021
CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | TBD | US | 2020
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Emerging Therapies – Chimeric Antigen (CAR) T-Cell Therapy – Special Topics – US (Wave 3)
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Emerging Therapies – Chimeric Antigen (CAR) T-Cell Therapy – Special Topics – US (Wave 2)
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Special Topics | CAR-T | Wave 1 | US | 2017
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
